Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-STAR 1-01 study of TUB-030 in advanced solid tumors
2025-522517-35-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of GS-8823 in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by Gilead Sciences. Planned start Dec 2025; status: authorised.
02
Drugs
GS-8823
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2025-522517-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522517-35-00.